Dr. Rajamannan's Schools

• Mayo Medical School , Class of 1989 MD in Medicine Mayo Medical School (MMS) enrolls a select class of 50 medical students each year. Our students are high-achieving women and men from all over the world who possess superior academic credentials, leadership characteristics, and a sincere dedication to service.

• University of Notre Dame , Class of 1985 Bachelors in Cellular/Molecular Biology and Public Health and Biochemistry The College consists of 5 academic departments and 15 research institutes and centers. There are over 1,200 undergraduate students and 145 full time teaching and research faculty with impressive awards and accolades. Our Faculty have generated over 35 million dollars in research grants and awards over the last year.

Dr. Rajamannan's Affiliations

• American Medical Association 1989

• American College of Cardiology 1998 Affiliate in Training

• American Society of Echocardiography 1999

• American College of Cardiology 2000 Fellow and Member

Dr. Rajamannan's Publications

• Experimental hypercholesterolemia induces apoptosis in aortic valves., Dr. Rajamannan January, 2001

• Serotonin mediated proliferation and matrix production of valvular tissue in carcinoid heart disease, J Heart Valve Dis January, 2001

• Employing Statin Drugs to Treat Calcific Aortic Stenosis: Part 1, Dr. Rajamannan October, 2011 A skilled cardiologist with over two decades of clinical experience, Dr. Nalini Rajamannan works as an Associate Professor and Medicine Advisor at Northwestern University, undertaking a dual leadership role at the institution’s Department of Pathology. The author of more than 40 peer-reviewed articles, case studies, and research abstracts, Dr. Rajamannan presently acts as an editor for the American Journal of Nephrology, concurrently reviewing work submitted to the Journal of Heart Valve Disease by medical professionals. Exploring a wide array of topics in her own scholarly writing, she has delved into the potential of utilizing statin drugs to inhibit progressively worsening calcific aortic stenosis. This particular piece was published in Current Cardiology Reports, a highly respected medical journal. Most commonly affecting adults 75 years of age or older, calcific aortic stenosis is defined as abnormal hardening that occurs in one or more of the heart’s valves. Often necessitating heart valve replacement surgery, calcific aortic stenosis can be fatal if left unaddressed. At this point in time, medical science has yet to identify a foolproof pharmacological approach to correcting the adverse effects of the disease, although physicians like Dr. Rajamannan are constantly seeking new avenues of treatment through innovative research. According to statistics obtained by U.S. News & World Report, three percent of adults will fall victim to calcific aortic stenosis during the final decades of life. When viewed in comparison with documented instances of other cardiac problems, this number may seem less significant. Nevertheless, specialists in the field of cardiology remain firmly committed to studying calcific aortic stenosis, potentially identifying a link between the condition and the widespread epidemic of dangerously elevated cholesterol. With conclusive research still in its early phases, medical science has discovered that cholesterol-lowering statin drugs do hold limited promise as an actionable method of care for patients diagnosed with calcific aortic stenosis.

• Mitral Valve Meeting, Coimbra, Portugal May, 2010 Lecturer

• Heart Valve Society of America, Valves in the Big Apple March, 2007 Lecturer

• Valvular Heart Disease Education Session , American College of Cardiology February, 2004 Lecturer

• Advances in Mineral Metabolism January, 1995 Invited Speaker

Dr. Rajamannan's Links